Published in Mol Pharm on June 28, 2013
Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging (2015) 0.97
⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem (2014) 0.94
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng (1999) 3.64
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
(11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging (2006) 1.79
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med (2007) 1.67
Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem (1987) 1.64
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol (2006) 1.52
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate (2008) 1.36
Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol (2005) 1.31
18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med (2007) 1.25
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem (2003) 1.23
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem (2001) 1.21
Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry (2008) 1.17
Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew Chem Int Ed Engl (2009) 1.14
Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res (2009) 1.14
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10
Prostate-specific membrane antigen-based therapeutics. Adv Urol (2011) 1.06
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med (2011) 1.05
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett (2010) 1.01
Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol (2009) 0.98
Prodrug forms of N-[(4-deoxy-4-amino-10-methyl)pteroyl]glutamate-gamma-[psiP(O)(OH)]-glutarate, a potent inhibitor of folylpoly-gamma-glutamate synthetase: synthesis and hydrolytic stability. J Med Chem (2006) 0.96
Molecular imaging of prostate cancer. Methods (2009) 0.92
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget (2011) 0.92
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate (2012) 0.91
Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency. Bioconjug Chem (2011) 0.88
A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. J Med Chem (2010) 0.85
Recent advances in copper radiopharmaceuticals. Curr Radiopharm (2011) 0.81
Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer. Clin Nucl Med (2008) 0.78
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004) 3.57
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One (2009) 2.68
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem (2005) 2.58
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45--a pilot study. Clin Cardiol (2015) 2.01
Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res (2004) 1.89
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig Dis Sci (2010) 1.87
Essential role of STAT3 in body weight and glucose homeostasis. Mol Cell Biol (2004) 1.74
Synthesis, characterization, reactivity, and catalytic potential of model vanadium(IV, V) complexes with benzimidazole-derived ONN donor ligands. Inorg Chem (2006) 1.70
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A (2009) 1.69
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem (2002) 1.68
Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. J Neurosci (2003) 1.62
Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett (2004) 1.57
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem (2002) 1.55
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer (2006) 1.54
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol (2007) 1.52
Mutation of SENP1/SuPr-2 reveals an essential role for desumoylation in mouse development. Mol Cell Biol (2005) 1.52
AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest (2003) 1.52
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Effect of Moringa oleifera Lam. leaves aqueous extract therapy on hyperglycemic rats. J Ethnopharmacol (2009) 1.48
Diospyrin derivative, an anticancer quinonoid, regulates apoptosis at endoplasmic reticulum as well as mitochondria by modulating cytosolic calcium in human breast carcinoma cells. Biochem Biophys Res Commun (2011) 1.47
Slitlamp, specular, and light microscopic findings of human donor corneas after laser-assisted in situ keratomileusis. Arch Ophthalmol (2004) 1.46
Nodal signaling recruits the histone demethylase Jmjd3 to counteract polycomb-mediated repression at target genes. Sci Signal (2010) 1.45
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Selective prostate cancer thermal ablation with laser activated gold nanoshells. J Urol (2007) 1.42
Luminescent gold nanoparticles with efficient renal clearance. Angew Chem Int Ed Engl (2011) 1.41
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Chemical composition of root aroma of Decalepis arayalpathra (J. Joseph and V. Chandras.) Venter, an endemic and endangered ethnomedicinal plant from Western Ghats, India. Nat Prod Res (2014) 1.39
Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J Exp Med (2007) 1.38
64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med (2005) 1.35
The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol (2004) 1.35
Ultralight multiwalled carbon nanotube aerogel. ACS Nano (2010) 1.32
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol Microbiol (2002) 1.29
Sim1 gene dosage modulates the homeostatic feeding response to increased dietary fat in mice. Am J Physiol Endocrinol Metab (2004) 1.29
Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J (2006) 1.28
Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics (2002) 1.28
Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res (2010) 1.26
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res (2008) 1.25
A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis. EMBO J (2006) 1.24
Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed (2012) 1.23
p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene (2002) 1.22
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res (2010) 1.20
Effects of cerium oxide nanoparticles on the growth of keratinocytes, fibroblasts and vascular endothelial cells in cutaneous wound healing. Biomaterials (2012) 1.20
Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol (2008) 1.20
Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res (2007) 1.18
The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol Pharm (2008) 1.18
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol (2007) 1.18
Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci U S A (2009) 1.17
Nanoscale control of phase variants in strain-engineered BiFeO₃. Nano Lett (2011) 1.16
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One (2012) 1.15
Unveiling the mechanism of uptake and sub-cellular distribution of cerium oxide nanoparticles. Mol Biosyst (2010) 1.15
Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew Chem Int Ed Engl (2009) 1.14
Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Angew Chem Int Ed Engl (2012) 1.14
Proteomic investigations of lysine acetylation identify diverse substrates of mitochondrial deacetylase sirt3. PLoS One (2012) 1.13
Acute myocardial infarction due to blunt chest trauma. Indian Heart J (2003) 1.13
Transplantation of mesenchymal stem cells from young donors delays aging in mice. Sci Rep (2011) 1.13
Cerium oxide nanoparticles scavenge nitric oxide radical (˙NO). Chem Commun (Camb) (2012) 1.13
Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol (2012) 1.12
Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem (2002) 1.12
Proteomic analysis of Chinese hamster ovary cells. J Proteome Res (2012) 1.11
Acute exposure of uranyl nitrate causes lipid peroxidation and histopathological damage in brain and bone of Wistar rat. J Environ Pathol Toxicol Oncol (2007) 1.11
Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone (2009) 1.10
The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res (2005) 1.08
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc (2010) 1.08
p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis (2002) 1.08
Re: Degirmenci et al.: Outcomes of ureteroscopy for the management of impacted ureteral calculi with different localizations (Urology 2012;80:811-815). Urology (2013) 1.08
Loop-mediated isothermal amplification of DNA (LAMP): a new diagnostic tool lights the world of diagnosis of animal and human pathogens: a review. Pak J Biol Sci (2014) 1.07
BF3 x OEt2-mediated highly regioselective S(N)2-type ring-opening of N-activated aziridines and N-activated azetidines by tetraalkylammonium halides. J Org Chem (2010) 1.07
PI3K/Akt to GSK3β/β-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cell Signal (2012) 1.07
Re: Koraitim: predictors of erectile dysfunction post pelvic fracture urethral injuries: a multivariate analysis (Urology 2013;81:1081-1085). Urology (2013) 1.06
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer (2008) 1.06
Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data. J Expo Sci Environ Epidemiol (2010) 1.05
PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc (2009) 1.05
Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules (2007) 1.05
Re: Lee et al.: factors indicating renal injury in pediatric bilateral ureteropelvic-junction obstruction (Urology 2013;81:873-879). Urology (2013) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
Identification and phylogenetic analysis of orf viruses isolated from outbreaks in goats of Assam, a northeastern state of India. Virus Genes (2012) 1.04
The effect of the amide substituent on the biodistribution and tolerance of lanthanide(III) DOTA-tetraamide derivatives. Invest Radiol (2008) 1.04
Mobility after hospital discharge as a marker for 30-day readmission. J Gerontol A Biol Sci Med Sci (2012) 1.03
Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson's disease. Mol Imaging Biol (2012) 1.03
Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol (2006) 1.03
The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. Biomaterials (2012) 1.03
Immunomodulatory and therapeutic potentials of herbal, traditional/indigenous and ethnoveterinary medicines. Pak J Biol Sci (2012) 1.02
In vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled drug delivery. Nanomedicine (2010) 1.02
Novel synthetic ligands for targeted PET imaging and radiotherapy of copper. Bioorg Med Chem Lett (2007) 1.02
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer (2007) 1.02
The relative cost of biomass energy transport. Appl Biochem Biotechnol (2007) 1.02
Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression. Am J Nucl Med Mol Imaging (2011) 1.01